AP-7-168 Stabilizes β2AR Homodimerization as Molecular Glue

Researchers have identified AP-7-168, an optimized derivative of a β-arrestin-biased negative allosteric modulator for the β2-adrenergic receptor (β2AR), which functions as a molecular glue to stabilize β2AR homodimerization. This discovery, published online in Nature on August 19, 2026, with the DOI 10.1038/s41586-026-10892-y, sheds new light on the complex mechanisms governing receptor function and signaling pathways. The β2-adrenergic receptor is a G protein-coupled receptor (GPCR) that plays a crucial role in mediating the effects of adrenaline and noradrenaline in the body, influencing processes such as heart rate, bronchodilation, and metabolism. Its signaling is tightly regulated, and dysregulation is implicated in various diseases, including asthma, cardiovascular disorders, and metabolic syndrome. Allosteric modulators are compounds that bind to a receptor at a site distinct from the primary ligand-binding site, thereby altering the receptor's response to its natural ligand. Negative allosteric modulators (NAMs) reduce the receptor's activity, while positive allosteric modulators (PAMs) enhance it. In this case, AP-7-168 is described as a "β-arrestin-biased" modulator, indicating that it preferentially influences the signaling pathway involving β-arrestin proteins over the canonical G protein pathway. This bias is significant because β-arrestin-mediated signaling can lead to different cellular outcomes, including receptor desensitization and internalization, which are critical for regulating receptor activity over time. The term "molecular glue" refers to a molecule that promotes the association of two or more other molecules that would not typically bind strongly together. In this context, AP-7-168 is shown to stabilize the formation of homodimers of the β2AR. Receptor dimerization, where two identical receptor units associate, is a common mechanism for GPCRs to modulate their signaling properties, affecting ligand binding affinity, receptor activation, and downstream signaling cascades. The stabilization of β2AR homodimers by AP-7-168 suggests a novel mechanism for controlling β2AR activity. This finding could have significant implications for the development of new therapeutic agents targeting the β2AR. By understanding how AP-7-168 promotes homodimerization and influences β-arrestin bias, scientists may be able to design drugs with improved efficacy and reduced side effects for conditions where β2AR modulation is beneficial. Further research will likely focus on elucidating the precise structural interactions between AP-7-168 and the β2AR homodimer, as well as the downstream consequences of this stabilized complex on cellular signaling. This work contributes to the broader field of GPCR pharmacology, where the precise control of receptor activity through allosteric modulation and the understanding of receptor oligomerization are key areas of investigation for drug discovery and development.